Radioiodine therapy with 131I is used for treatment of suspected recurrence of differentiated thyroid carcinoma. Pre-therapy 124I PET/CT with a low activity (~1% of 131I activity) can be performed to determine whether uptake of 131I, and thereby the desired therapeutic effect, may be expected.
INTRODUCTION
Radioiodine therapy with 131I is used for the primary treatment of differentiated thyroid carcinoma by ablating remnant thyroid tissue and potential residual tumor tissue after thyroid resection. Treatment with 5.5-7.4 GBq of 131I is indicated if a patient is suspected of metastases (1) . The administered activity of 131I is generally empiric and non-patient-specific, since the uptake and hence the therapeutic effectiveness of radioiodine in metastatic lesions is usually not known beforehand. Post-therapy 131I SPECT/CT and/or whole body scintigraphy is routinely performed to assess tumor uptake. Up to 50% of empirically treated patients show no uptake on the post-therapy imaging (2) . To predict whether uptake of radioiodine, and hence a desired therapeutic effect, may be expected, pre-therapy imaging with a low activity is performed.
Several pre-therapy imaging strategies have been suggested to optimize patient-specific treatment activity and to prevent unnecessary 131I therapies. 131I whole-body scintigraphy with a low non-therapeutic activity of 131I (half-life 8 days) can be used for pre-therapy imaging (3) . However, diagnostic low activity scintigraphy with 131I does not adequately predict the results of post-therapeutic high activity 131I scintigraphy (4) . Moreover, septal penetration by the high-energy (364 keV and 637 keV) gamma photons negatively affects the image quality of 131I SPECT and scintigraphy, which makes 131I less suitable for diagnostic purposes. The medium energy (159 keV) gamma emitter 123I has also been suggested for pre-therapy imaging and studies investigating the potential of 123I yielded good results (e.g. (5)). However, due to the short half-life of 123I (13.2 h) a large fraction of the administered activity has already decayed before the maximum uptake is achieved and imaging is performed.
Alternatively, 124I with a half-life of 4.2 days has been proposed for pre-therapy imaging and assessment of treatment response. Several groups have reported promising results using 124I as a diagnostic agent (6, 7) . 124I is a positron emitter and can be imaged with PET, with superior resolution, by on November 7, 2017. For personal use only. jnm.snmjournals.org Downloaded from sensitivity and quantitation as compared with scintigraphy or SPECT used for 131I. Relatively low activities of 20 -74 MBq are used for diagnostic 124I PET imaging (8) (9) (10) (11) (12) (13) .
Unfortunately, clinical experiences have shown that 124I PET/CT does not always predict uptake of 131I reliably, and discrepancies between post-therapy 131I SPECT/CT and pre-therapy 124I PET/CT have been reported by several groups (8) (9) (10) (11) (12) (13) . More specifically, in some cases no uptake was found on 124I PET/CT images, whereas uptake was found on 131I SPECT/CT images. An example from a study we performed (unpublished data) is shown in Figure 1 (14) . These false negative 124I PET/CTs as compared with 131I SPECT/CTs may be ascribed to a difference in detectability of lesions on 124I PET/CT and 131I SPECT/CT.
The purpose of this study was to investigate whether the reported discrepancies may be ascribed to a difference in detectability of lesions on 124I PET/CT and 131I SPECT/CT, and hence, to determine whether the administered activity of 124I is sufficient to achieve equal detectability. This was done by establishing the activity concentration of 124I expressed as a percentage of the 131I activity concentration at which the contract-to-noise ratio was equal for both modalities.
MATERIALS AND METHODS

Phantom
To compare the detectability of lesions on 131I SPECT/CT and 124I PET/CT images, acquisitions of the IEC NEMA 2007 phantom (PTW, Freiburg, Germany) were performed with varying activity concentrations. The phantom is torso-shaped and has a lid holding refillable thin-walled spheres of 10, 13, 17, 22, 28 and 37 mm in diameter. Separate phantoms were used for 124I and 131I experiments. The phantoms were filled only once and different activity concentrations were obtained by leaving the activity to decay. This approach decreases measurement errors in comparison with refilling the by on November 7, 2017. For personal use only. jnm.snmjournals.org Downloaded from phantom. Two phantoms were used for detectability analysis; one with activity in the background compartment and one without.
Clinically, large variations may occur in lesion to background ratios. Rubello et al. have performed measurements of the lesion-to-background ratio with a gamma probe during radio-guided surgery, and they obtained a mean lesion-to-background ratio of 11.4 (15) . Therefore, we used two phantoms with different background concentrations to capture both extremities; no background (1:0) and a high background concentration (10:1). The activity concentration in the spheres ranged from 1.8x10 4 Bq/ml to 4.6 Bq/ml for 124I and from 9.1x10 5 Bq/ml to 3.9x10 2 Bq/ml for 131I. The initial activity concentrations are shown in Supplemental Table 1 . The activity concentration in the phantoms was chosen such that it could be used to effectively compare the detectability of lesions in the range around the expected minimum detectable activity (MDA). In total, 45 124I PET acquisitions were acquired over a period of 50 days. Similarly, 42 131I SPECT acquisitions were performed over a period of 90 days.
Scanners and acquisition
A Siemens Biograph mCT Time-of-Flight (TOF) PET/CT scanner (Siemens Healthcare, Erlangen, Germany) with TrueV (axial field of view 21.6 cm) was used to acquire PET data. 124I images were acquired using a 435-650 keV energy window in 4 minutes per bed position, in accordance with the clinical protocol (14) . Three bed positions were used to ensure that the sensitivity was uniform along the entire length of the phantom in the axial direction.
A dual-headed Siemens Symbia T16 (Siemens Healthcare, Erlangen, Germany) SPECT/CT system was used to acquire SPECT images. The Siemens BiCore high-energy (HE) (Siemens Healthcare, Erlangen, Germany) collimator that was used has 8000 holes, a hole length of 59. voxel size. The Siemens Flash 3D reconstruction algorithm was used, incorporating attenuation correction and resolution recovery using distance dependent PSFs. Three reconstruction methods were used to obtain SPECT images. The first method used 6 iterations with 8 subsets and triple-energywindow scatter correction (SC 6i8s), the second method used 6 iterations with 8 subsets and did not incorporate scatter correction (no-SC 6i8s) and the third method used 30 iterations with 8 subsets and by on November 7, 2017. For personal use only. jnm.snmjournals.org Downloaded from triple-energy-window scatter correction (SC 30i8s). Reconstructions with 6 iterations and 8 subsets were performed to allow comparison with the clinical trial running at our hospital (14) , whereas reconstructions with 30 iterations and 8 subsets were included for increased contrast recovery at the cost of increased image noise (18, 19) .
Quantitative analysis
Detectability Equivalence Percentage. As a measure of detectability, we calculated the contrast-tonoise ratio (CNR) for each sphere using where C H is the mean voxel value in the sphere volume of interest (VOI), C B is the mean voxel value in the background VOI and is the standard deviation in the background VOI.
Three-dimensional VOI masks were created based on the sphere coordinates determined from the co-registered CT. The position of the spheres in the CT image was determined automatically using a Hough-transform based circle detection method (20) . The background VOI was defined as the entire phantom minus the sphere VOIs. To eliminate the influence of partial volume effects on the background measurement, a 2 cm margin around the spheres and the phantom edges was subtracted from the background VOI by means of binary erosion.
To assess the difference in detectability of spheres on 124I PET/CT and 131I SPECT/CT, the 124I activity concentration was expressed as a percentage of the 131I activity concentration required to achieve the same CNR. This metric was defined as the detectability equivalence percentage (DEP). For example, a DEP of 1% indicates that the same CNR is obtained on the 124I PET/CT image as on the 131I
SPECT/CT image if the 124I activity concentration is 1% of the 131I activity concentration. The DEP was determined by calculating the average ratio of the CNR curves (CNR versus activity concentration) for the by Figure   2 for the phantom with and without background activity, respectively. Defined as the average ratio between 124I and 131I activity concentration to achieve the same CNR, the DEP was calculated for each combination of PET and SPECT reconstruction methods and for each sphere size ( Table 1 and Table 2 ).
RESULTS
In general, lower DEPs were obtained for smaller spheres, so that a relatively low 124I activity concentration is sufficient to achieve a similar detectability of lesions with 124I PET/CT as with 131I SPECT/CT. Furthermore, the DEP depends on the reconstruction method that is used. The DEP is higher for the no-PSF no-TOF PET reconstruction method than for the PSF TOF reconstruction method.
Furthermore, the DEP is slightly higher for the SC 6i8s method than for the no-SC 6i8s method, and lower for the SC 30i8s method than for the other SPECT reconstruction methods. The differences between DEPs for the PSF TOF and no-PSF no-TOF reconstruction methods are smaller for the phantom without activity in the background compartment. In general, the DEPs are slightly smaller for the phantom without activity in the background compartment. Table 3 shows the MDA for the phantom with activity in the background compartment. The MDA of 124I is lower for the PSF TOF reconstruction method than for the no-PSF no-TOF reconstruction method. Similarly, for the 13 and 17 mm spheres, the MDA of 131I is lower for the SC 6i8s reconstruction method than for the no-SC 6i8s reconstruction method. However, for the 10, 22 and 28 mm spheres, the MDA of 131I is higher for the SC 6i8s reconstruction method than for the no-SC 6i8s reconstruction method. The MDAs of the SC 30i8s reconstruction method are larger than for the other SPECT reconstruction methods. However, as different scan delay times are used after administration, it is necessary to correct for physical decay during the scan delay time. The 124I PET and the 131I SPECT acquisitions are usually performed 24 hours and 7 days after administration respectively, so that at scan time the 124I activity concentration is approximately 1.5% of the 131I activity concentration, if we correct for physical decay. Table 1 and Table 2 show that for some sphere sizes and reconstruction algorithms, the DEP is smaller than 1.5%. Therefore, for small spheres (≤10mm) on PSF TOF PET an activity of 74 MBq 124I is sufficient to achieve similar detectability on the low activity 124I PET/CT as on the high activity 131I SPECT/CT. This shows that false negative low activity 124I PSF TOF PET/CTs as compared with the post-therapy high activity 131I SPECT/CTs are not likely occurring owing to differences in detectability for small lesions. A significant part of the lesions in clinical practice is expected to be smaller than 10 mm (24) 
lesions (>10 mm) and no-PSF no-TOF PET, the DEP generally is larger than 1.5% and 74 MBq of 124I is not sufficient to achieve similar detectability on the low activity 124I PET/CT as on the high activity 131I SPECT/CT. Reported discrepancies, such as shown the example in Figure 1 , may therefore be caused by differences in the detectability.
The administered activity of 124I is a factor that should be taken into account when comparing our results with other studies. Several clinical studies have been performed with lower activities than 74
MBq of 124I (8, 9, 11) . The probability of a false negative 124I PET/CT as compared with the post-therapy 131I SPECT/CTs considerably increases with lower 124I dosages. When 25 MBq of 124I and 7400 MBq of 131I is administered, the ratio of 124I and 131I activity concentration is approximately 0.5%, when corrected for physical decay. Since this is lower than the reported DEPs, discrepancies are more likely to occur as a result of differences in detectability.
Activities of 90 MBq are sufficient to achieve similar detectability for lesion diameters up to 17 mm on PSF TOF PET, with DEPs up to 1.8%. Based on DEPs of 3.5% for lesion diameters up to 17mm on no-PSF no-TOF PET, activities as high as 170 MBq of 124I may be warranted to obtain equal detectability.
However, a limiting factor for high pre-therapy activities may be thyroid stunning, although stunning due to 124I is controversial, and the origin and existence of stunning still are a hotly debated issue (25) .
Discrepancies between the 124I and 131I distributions in the tissue as a consequence of differences in uptake/washout may be influenced by additional factors, not assessed in this study. Firstly, unlike phantoms, thyroid tumors or thyroid cancer metastases are inhomogeneous structures consisting of cancer cells, blood vessels and connective tissue with different iodine concentrations, inducing partial volume effects which may affect the measured contrast. Secondly, the uptake of iodine may be influenced by the preparation of the patient, since patients can be prepared either by thyroid hormone withdrawal or recombinant human thyroid-stimulating hormone (rhTSH) stimulation to stimulate iodine by on November 7, 2017. For personal use only. jnm.snmjournals.org Downloaded from uptake. Thirdly, cell damage as a consequence of delivered dose may influence the retention time and may therefore cause differences in the 124I and 131I physiological washout properties. A faster washout of 131I is expected for damaged cells (24) . Fourthly, the contrast of 131I lesions may increase when delayed scanning is performed, because clearance of the background activity can occur at a faster rate than clearance of the activity in the tumor, so that contra-intuitively, the contrast in the images increases over time (10) . One of the few practically adjustable parameters in clinical practice that influences the activity concentration is the delay time between the administration and acquisition. However, the timing of the 131I SPECT/CT acquisition still is a matter of debate in literature. In fact, Salvatori et al. state that 'perfect timing' probably does not exist due to differences in 131I kinetics in different patients and in different metastases (26) . A scan delay time of 7 days for this study was chosen to allow washout of background activity (27) . Similar to 131I, the uptake of 124I in metastases shows significant differences among metastases, although most of the metastases showed to have their peak uptake at approximately 24 hours after administration (28, 29) . Therefore, a scan delay time of 24 hours was used for the 124I PET/CT acquisition.
The purpose of this study was not to investigate the impact of physiological factors, but to quantitatively compare the detectability of lesions on 124I PET/CT and 131I SPECT/CT images. Assuming that physical decay is the only factor affecting the ratio of 124I and 131I activity concentration may not be accurate and the interpretation of the results depends on these assumptions. However, the measured DEPs do not depend on physiological factors. To our knowledge, phantom measurements that compare the detectability of 124I and 131I quantitatively have not been published before.
CNR values lower than 1 were not used for the regression analysis and calculation of the DEP.
These values are inherently noisy due to the low number of counts. Furthermore, rounding errors occurred by conversion to the DICOM format when the mean voxel value in the background by on November 7, 2017. For personal use only. jnm.snmjournals.org Downloaded from compartment was lower than 1. Consequently, for low activity concentrations in the phantom without background activity, the standard deviation in the background compartment σ B was underestimated and the CNR overestimated. Therefore, these data points (mean background VOI<1) were not used to determine the DEPs and MDAs.
Diagnostic 131I SPECT/CT with 37-150 MBq of 131I can also be performed for pre-therapy imaging (3) . However, this study shows that false negative diagnostic scans as compared with the posttherapy scans may be ascribed to the difference in activity that is used, and that false negative results are likely, especially for the smaller lesions that have high MDAs.
False negative 124I PET/CTs as compared with the 131I SPECT/CTs occur when the 124I activity concentration is below minimum detectable activity (MDA) and 131I concentration is above MDA. The
MDAs of 131I and 124I were therefore determined for the different reconstruction methods. The MDA of 131I was higher for the SC 6i8s reconstruction method than for the no-SC 6i8s reconstruction method for some sphere sizes (10, 22 and 28 mm). MDAs were not necessarily lower for images obtained with scatter correction, possibly due to the addition of noise introduced in the reconstruction by the noisy scatter projections. Unfortunately, no 131I MDAs could be obtained for the 37 mm spheres because not enough data was available for low CNRs.
The DEPs were lower for the 30i8s than for the 6i8s SPECT reconstruction method, because generally lower CNRs were obtained for the 30i8s than for the 6i8s SPECT reconstruction method. This was caused by the fact that the background noise level in the images increased with the number of iterations, which lowered the CNR. Therefore, the 124I activity concentration expressed as a percentage of the 131I activity concentration required to achieve the same CNR (i.e. the DEP), was lower for the 30i8s than for the 6i8s SPECT reconstruction method. 
